Mikami K - Search Results

1

Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma.

Hagiwara N, Watanabe M, Iizuka-Ohashi M, Yokota I, Toriyama S, Sukeno M, Tomosugi M, Sowa Y, Hongo F, Mikami K, Soh J, Fujito A, Miyashita H, Morioka Y, Miki T, Ukimura O, Sakai T. Hagiwara N, et al. Among authors: mikami k. Cancer Lett. 2018 Sep 1;431:182-189. doi: 10.1016/j.canlet.2018.05.025. Epub 2018 May 17. Cancer Lett. 2018. PMID: 29778569

2

[Management of side effects of everolimus treatment for metastatic renal cell carcinoma].

Mikami K, Hongo F, Miki T. Mikami K, et al. Hinyokika Kiyo. 2012 Nov;58(11):647-50. Hinyokika Kiyo. 2012. PMID: 23254794 Free article. Japanese.

3

Radio-frequency ablation of renal cell carcinoma in patients who were at significant risk.

Ukimura O, Kawauchi A, Fujito A, Mizutani Y, Okihara K, Mikami K, Soh J, Nakamura T, Nakanishi H, Ushijima S, Miki T. Ukimura O, et al. Among authors: mikami k. Int J Urol. 2004 Dec;11(12):1051-7. doi: 10.1111/j.1442-2042.2004.00966.x. Int J Urol. 2004. PMID: 15663674 Free article. Clinical Trial.

4

[The second-line chemotherapy for urological cancers].

Miki T, Mikami K, Mizutani Y. Miki T, et al. Among authors: mikami k. Gan To Kagaku Ryoho. 2005 Jan;32(1):33-8. Gan To Kagaku Ryoho. 2005. PMID: 15675579 Review. Japanese.

5

The significance of the expression of dihydropyrimidine dehydrogenase in prostate cancer.

Li Y, Mizutani Y, Shiraishi T, Nakamura T, Mikami K, Takaha N, Okihara K, Kawauchi A, Sakai T, Miki T. Li Y, et al. Among authors: mikami k. BJU Int. 2007 Mar;99(3):663-8. doi: 10.1111/j.1464-410X.2006.06606.x. Epub 2006 Nov 7. BJU Int. 2007. PMID: 17092280

6

Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis.

Mizutani Y, Nakanishi H, Li YN, Matsubara H, Yamamoto K, Sato N, Shiraishi T, Nakamura T, Mikami K, Okihara K, Takaha N, Ukimura O, Kawauchi A, Nonomura N, Bonavida B, Miki T. Mizutani Y, et al. Among authors: mikami k. Int J Oncol. 2007 Apr;30(4):919-25. Int J Oncol. 2007. PMID: 17332931

7

Radiofrequency ablation for renal tumors: our experience.

Hiraoka K, Kawauchi A, Nakamura T, Soh J, Mikami K, Miki T. Hiraoka K, et al. Among authors: mikami k. Int J Urol. 2009 Nov;16(11):869-73. doi: 10.1111/j.1442-2042.2009.02378.x. Epub 2009 Sep 3. Int J Urol. 2009. PMID: 19735313

8

Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.

Mizutani Y, Matsubara H, Yamamoto K, Nan Li Y, Mikami K, Okihara K, Kawauchi A, Bonavida B, Miki T. Mizutani Y, et al. Among authors: mikami k. Cancer. 2004 Oct 15;101(8):1794-802. doi: 10.1002/cncr.20550. Cancer. 2004. PMID: 15386310 Free article.

9

Significance of serum tumor necrosis factor-related apoptosis-inducing ligand as a prognostic biomarker for renal cell carcinoma.

Toiyama D, Takaha N, Shinnoh M, Ueda T, Kimura Y, Nakamura T, Hongo F, Mikami K, Kamoi K, Kawauchi A, Miki T. Toiyama D, et al. Among authors: mikami k. Mol Clin Oncol. 2013 Jan;1(1):69-74. doi: 10.3892/mco.2012.35. Epub 2012 Oct 15. Mol Clin Oncol. 2013. PMID: 24649125 Free PMC article.

10

Clinical utility of ursodeoxycholic acid in preventing flutamide-induced hepatopathy in patients with prostate cancer: a preliminary study.

Kojima M, Kamoi K, Ukimura O, Fujito A, Nakao M, Tanaka S, Miyashita H, Iwamoto N, Ohe H, Kitamori T, Date S, Kitamura K, Araki H, Aoki T, Imada N, Takada H, Imaide Y, Mikami K, Uchida M, Saitoh M, Miki T. Kojima M, et al. Among authors: mikami k. Int J Urol. 2002 Jan;9(1):42-6. doi: 10.1046/j.1442-2042.2002.00412.x. Int J Urol. 2002. PMID: 11972649 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

768 results

Search Page